Janssen Collaborates with Genmab For HexaBody-CD38
By Jasmine Kalsi & Michelle Liu
Pharma Deals Review: Vol 2019 Issue 6 (Table of Contents)
Published: 18 Jun-2019
DOI: 10.3833/pdr.v2019.i6.2435 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Complementing its growing haematology franchise, Janssen Biotech has entered into a global license and option agreement with Genmab to develop and commercialise its preclinical candidate, HexaBody-CD38...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS